


Supplementary Figure 1. *CDH1* mRNA is significantly upregulated in some carcinoma subtypes and remains unchanged across major tumor stages of most carcinomas. *CDH1* mRNA levels are significantly upregulated in the two subtypes of pancreatic carcinoma: classical (T=86) and basal (T=65) compared to the normal tissues (N=171) (A) and in the three subtypes of lung carcinoma: proximal inflammatory (T=78), proximal proliferative (T=58), and terminal respiratory unit (T=68) compared to the normal tissues (N=347) (B). Grey, normal; red, carcinoma in (A) and (B). The levels of *CDH1* mRNA remain unchanged across the major stages of colon (C), pancreatic (D), lung (E), and endometrial (F) carcinomas. **, $p < 0.01$.



Supplementary Figure 2. E-cad protein is either upregulated or remains unchanged in most major tumor stages. E-cad levels are either significantly upregulated or remain unchanged in distinct stages of endometrial carcinoma (A), lung carcinoma (B), ovarian carcinoma (C), head/neck carcinoma (D), and colon carcinoma (E and F) except for stage 1 of head/neck carcinoma (D) compared to the corresponding normal tissues. Numbers of tissues used in the

analysis are: endometrial carcinoma: normal, n=31, stage 1, n=74, stage 2, n=8, stage 3, n=15; lung cancer: normal, n=11, stage 1, n=59, stage 2, n=30, stage 3, n=21; ovarian cancer: normal, n=25, stage 1, n=2, stage 3, n=75, stage 4, n=16; head/neck carcinoma: normal, n=71, stage 1, n=7, stage 2, n=25, stage 3, n=75, stage 4, n=4; colon carcinoma: normal, n=100, mucinous, n=19, non-mucinous, n=77, stage 1, n=10, stage 2, n=39, stage 3, n=40, stage 4, n=8. *, $p < 0.05$, **, $p < 0.01$.